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Introduction 
 Pancreatic neuroendocrine tumors (PanNENs) are rare malignancies with a 
good prognosis, especially when compared to their exocrine counterpart. PanNENs 
are divided into functioning (F-PanNENs) and non-functioning (NF-PanNENs) 
subtypes, based on hormone production. They are characterized by low mitotic 
rates, determined using histopathology1. The biology of these tumors is complex2 
and there are currently no reliable markers of biological behaviour. One of the most 
adopted tool in this setting is the calculation of the Ki-67 index. The World Health 
Organization (WHO)3  and the European Neuroendocrine Tumor Society (ENETS) 
4 Guidelines rely on the Ki-67 index to discriminate three categories of tumors (G1 
for of Ki-67 index values < 2%, G2 for values between 3% and 20%, G3 for values 
> 20%). While surgery is recommended for F-PanNENs, for resectable non-
metastatic NF-PanNENs, surgery should only be considered when the tumor is over 
20 mm in diameter in cases with symptoms, with G2 or G3 tumors, for smaller 
tumors when non-surgical management is contraindicated, or according to patient’s 
wishes. Instead, for tumors smaller than 20 mm and graded as G1 or low G2, 
surveillance is sufficient. Several clinical studies have demonstrated that the 
histological Ki-67 index value is a valid indicator of the tumor’s biology 5-8. The 
ability to obtain a cytological Ki-67 index value at the time of diagnosis using fine-
needle aspiration (FNA) is highly clinically valuable and in need of further 
investigation. 
 Considering that pancreatic surgery is still burdened by high rates of 
morbidity and mortality 9, tailored treatment based on a proper analysis of the 
biology of the tumor might improve patient outcome. For example, small NF-
PanNENs with high preoperative Ki-67 index values may benefit from surgery 
regardless of dimensions; however, high Ki-67 index values might cause the 
surgeon to perform a standard pancreatic resection (over a parenchyma-sparing 
one) or a regional lymphadenectomy. 
 It remains unclear whether the preoperative Ki-67 index value accurately 
represents the postoperative Ki-67 index value of the resected tumor, as some 
studies describe a good correlation while others do not10-18. Recently, Weiss et al. 
reported the lack of a correlation between the preoperative FNA results and the final 
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histology, for both Ki-67 and grading, with an average difference in the former of 
5.9%. The authors state that preoperative FNA leads to under-grading the tumor 
and that this consequently results in undertreatment19. Intratumor cellular 
heterogeneity is a confounding factor that might be responsible for the dissonance 
between the pre- and postoperative analyses13, 20, 21. Furthermore, obtaining an 
adequate number of cells to determine a reliable Ki-67 index value using is 
challenging using FNA. 
 In this study, we address multiple issues. First, we establish the concordance 
rate between cytological and histological Ki-67 index values (cKi-67 and hKi-67) 
and grading (cG and hG). Second, we explore the possible differences between 
these rates when percutaneous ultrasound-guided (pUS) or endoscopic ultrasound-
guided (eUS) FNA is employed. Finally, we assessed the diagnostic rate of FNA.  
 
Materials and Methods 
Patient selection 
 Patients who underwent pancreatic resection from January 2011 to May 
2017 were selected from the prospectively maintained electronic database of the 
General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona 
Hospital Trust. Only patients with preoperative FNAs for a presumed PanNEN and 
postoperative histological analyses were included. Then, according to the issues 
addressed, multiple sub-cohorts were identified. The primary group included 
patients who submitted to resection after a preoperative presumed diagnosis of 
PanNENs. In this group, cKi-67 vs. hKi-67 and cG vs. hG were compared.  
 The second and the third sub-cohort groups were determined according to 
the technique used (pUS vs. eUS) and the diagnostic rate for each group was added 
to the main endpoint.  
 To ensure a homogeneous cohort, the following cases were excluded from 
this study: metastatic cases; multifocal cases; PanNENs that either at the 
preoperative FNA or upon final histology had a mixed neoplastic component (e.g. 
combinations of PanNENs and acinar cell carcinoma, mixed-adenoneuroendocrine 
carcinoma, or pancreatic adenocarcinoma); and PanNENs treated preoperatively 
with neoadjuvant therapy. The Ki-67 assessment was performed according to the 
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WHO 2017 Guidelines 3. To ensure accurate grading, at least 500 cells per cell 
block were counted. In our experience, cases without sufficient tumor cells in their 
cell blocks are rare and those were not considered for this study. A triple 
immunocytochemical analysis with synaptophysin, chromogranin, and Ki-67 was 
performed to determine the diagnostically-relevant neuroendocrine nature of the 
samples. 
 From 2015, each case was previously discussed at a dedicated and 
institutionalized multidisciplinary meeting. 
Population characteristics 
 Demographic, clinical, radiological, cytological, and histological data were 
obtained. PanNENs were classified according to the WHO criteria, including data 
regarding the differentiation status and Ki-67 index values. The institutional 
preoperative and surgical management of PanNENs has been previously 
described22. Patients submitted either to pUS-FNA or eUS-FNA for diagnosis, 
staging, and grading according to the specialist’s prescription, and, considering the 
site, the dimensions and the shape of the tumor. 
 
 pUS-FNA 
 Previous cross-sectional imaging was reviewed before FNA by the 
radiologist that would have been performed the FNA. Peripancreatic vessels were 
examined using Doppler US to determine the safest approach. Prior to the sampling 
procedure, routine sterile preparation of the abdominal wall was performed and a 
local anesthetic was injected at the chosen entry point. US-FNAs were performed 
by an experienced radiologist using a Sequoia 512 system (Acuson/Siemens 
Medical Solutions, Mountain View, CA, USA). Convex multi-frequency probes 
with a lateral guidance kit and 20 G or 21 G modified Menghini-type aspiration 
needles were used. A rapid on-site evaluation (ROSE) was performed after each 
procedure by experienced cytopathologists. The cytologic sample was immediately 
smeared onto a glass slide, fixed with 95% ethanol and stained using the modified 
Papanicolaou method.  
eUS-FNA 
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 This procedure was performed by two experienced endoscopists with 
caseloads greater than 350 eUS-FNA per year. Either a standard (EchoTip Ultra, 
Cook Medical, Limerick, Ireland) or, more frequently, a side-fenestrated (Echotip 
ProCore, Cook Medical) 25 G needle was used. The institutional-specific 
techniques are described in a previous publication 23. The ROSE was not available 
after EUS-FNA due to logistic reasons. 
Statistical analysis 
 Differences between groups were evaluated using the chi-square test. 
Fisher’s exact test was used when appropriate. The independent two-tailed t-test 
was used to compare the means of continuous numerical data. When Ki-67 was 
reported as < 1% then the value of zero was used. When Ki-67 was reported as a 
range, the greatest value was used. The correlation between pre- and postoperative 
Ki-67 index values and grading was calculated using Spearman's rho and/or 
Cohen’s kappa. A rho value of 0.00 - 0.19 was considered to be very weak, 0.20 - 
0.39 was weak, 0.40 - 0.59 was moderate, 0.60 - 0.79 was strong, and 0.80 - 1.00 
was very strong. A kappa value of 0.20 was considered to be poor, 0.21 - 0.40 was 
fair, 0.41 - 0.60 was moderate, 0.61 - 0.80 was good, and 0.81 - 1.00 was very good. 
 A Bland-Altman analysis was used to assess the correlation between cKi-67 
and hKi-67, where the difference between the measured values against their means 
was represented 24. The Bland-Altman analysis calculates the mean difference 
between 2 methods of measurement (the “bias”) and 95% LOA as the mean 
difference (1.96 SD). The Bland-Altman analysis calculates the mean difference 
between two methods of measurement (i.e. the “bias”) and 95% LOA as the mean 
difference (1.96 SD). The 95% CI for the limits were also determined. In this visual 
method, the smaller is the range between the two limits, the better is the agreement 
25.  
 The difference in Ki-67 index values (ΔKi-67) was calculated by subtracting 
the preoperative value from the postoperative one. The ΔKi-67 that were lower than 
-2% or greater than 2% were arbitrarily considered to be outliers and any possible 
variables were investigated using the chi-square test. All statistical tests were two-
sided, and P-values < 0.05 were considered statistically significant. These statistical 
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analyses were performed using SPSS (IBM, Armonk, NY, USA) and MedCalc 
(MedCalc Software, Ostend, Belgium). 
Results 
 The final study population consisted of 100 patients. Eighty-seven 
PanNENs were non-functioning and 13 tumors were functioning (12 insulinomas 
and one gastrinoma). eUS-FNA and pUS-FNA were performed in 85 and 15 cases 
respectively. Table 1 contains the demographic, clinical, pathological, surgical and 
radiological features of the study population. FNA was reached a diagnosis in 85 
patients. No periprocedural complications were reported.Eighty-five FNA were 
performed via eUS, the remaining 15 via pUS. No periprocedural complications 
were reported. 
Table 1. Demographic, clinical and surgical features of the study population 
Age (SD) 54 ± 12 years 
Sex (M/F) 48/52 
Symptoms, (yes, n, %) 
  Abdominal pain (any kind of) 
  Symptoms of insulinoma/gastrinoma 
  Jaundice 
  Acute pancreatitis 
30 (30%) 
15 (50%) 
13 (43.4%) 
1 (3.3%) 
1 (3.3%) 
Site 
  Head 
  Body 
  Tail 
 
46 (46%) 
33 (33%) 
20 (20%) 
Syndromic cases (MEN1) 3 (3%) 
Tumor diameter (mm, mean; SD) 
  ≤/> 20 mm (n, %) 
25.5 ± 19.1 
48/51 
(48/51%) 
eUS-FNA / pUS-FNA 
85/15 
(85/15%) 
cG 
  G1 
  G2 
  G3 
63 (74.1%) 
47 (74.6%) 
19 (20.6%) 
2 (4.8%) 
Surgery 
  DPS 
  PD 
  E 
  DPSP 
  MP 
  TPS 
 
35  
34  
12  
8  
7  
4  
eUS-FNA: Endoultrasound-guided fine-needle aspiration;  pUS-FNA: 
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percutaneous-guided; MEN1: Multiple endocrine neoplasia type 1;  
DPS: distal pancreatectomy with splenectomy; PD:  pancreatico- 
duodenectomy; E: enucleation; DPSP: distal  pancreatectomy with  
spleen preservation; Middle pancreatectomy; TP: total pancreatectomy;  
TPS: total pancreatectomy with splenectomy 
 
Diagnostic rate, concordance rates for diagnosis 
 In 84 of 100 presumed cases of PanNEN, a diagnosis was reached 
preoperatively. Non-diagnostic cases were biopsied using eUS and pUS in 15 
(15/85, 17.6%) and one (1/15, 6.6%) of the cases. Table 2 presents the pathologic 
data and concordance rates for diagnosis considering the final histology. The 
overall concordance rate for diagnosis was 97.6%. NF-PanNENs, the most common 
diagnosis, represented 65 of 76 cases (85.5%). The concordance rate for G3 tumors 
was 33.3%. Indeed, in one case only the cytology was accurate, while the remaining 
two cases were revealed to actually be G1 PanNENs with a Ki-67 index value of 
2% upon postoperative histological analysis. Notably, in these two cases, the 
cytology was obtained using a percutaneous approach. 
Table 2. Pathologic data 
Diagnosis from FNA  N  (%) 
Final 
histology 
  cG 
   G1 
   G2 
   G3 
63 (74.1%) 
47 (74.6%) 
13 (20.6%) 
3 (4.8%) 
 
- 
- 
- 
  Non-diagnostic 
   NF-PanNENs 
   MANEC 
   PanNENs G3  
   NEC with PC 
   cPanNEN 
- 
- 
- 
- 
- 
- 
16 (16%) 
11 (68%) 
2 (12.5%) 
1 (6.5%) 
1 (6.5%) 
1 (6.5%) 
  Diagnostic 
   NF-PanNEN 
   Insulinoma 
   Gastrinoma 
   cPanNEN 
84 (84%) 
68 (81%) 
12 (14.2%) 
1 (1.2%) 
3 (3.5%) 
All confirmed 
Nodal status (N+) 
   Overall 
    G1 
 
23 (23%) 
9 (39.1%, 19.1% of G1) 
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    G2 
    G3 
11 (47.9%, 52.6% of G2) 
3 (13%, 100% of G3) 
NF-PanNEN: non-functioning pancreatic neuroendocrine tumor;  
MANEC: Mixed Adenoneuroendocrine Carcinoma; NEC: neuroendocrine 
carcinoma; cPanNEN: cystic PanNEN 
 
Concordance rates for grading 
 The cG was available for 63 of 84 diagnostic samples (75%) and, therefore, 
this was the study population for the analysis of the reliability of cG. Assessment 
of hG was available for 98 of 100 patients. Discordance was observed in 17 of 63 
(26.9%) cases. The mean tumor diameter of the discordant cases was 35 ± 32 mm 
and of the concordant cases was 26 ± 16 mm (p = 0.001). The overall sensitivity for 
G was 76.2%, whereas for G1, G2, and G3 it was 76.6%, 84.6% and 33.3% 
respectively (Table 3).  
 
Table 3. Concordance rate for grading 
 
hG1 hG2 hG3 Total 
cG1 36 11 0 47 
cG2 2 11 0 13 
cG3 2 0 1 3 
Total 25 19 2 63 
 
The overall level of agreement between the pre- and postoperative grading was 
moderate (Cohen’s k = 0.455, 95% CI from 0.219 to 0.691, p < 0.001). When 
considering PanNEN less than 20 mm (n = 26, 41%) and greater than 20 mm (n = 
37, 59%), the agreement was moderate (k = 0.438, 95% CI from 0.070 to 0.79518, 
p = 0.014 and k = 0.450, 95% CI from 0.141 to 0.760, p < 0.001). When considering 
the whole cohort, Spearman's rho indicated a moderate positive agreement between 
the pre- and postoperative grading (rs = 0.430, 95% CI from 0.204 to 0.613, p < 
0.001). The agreement was moderate for both PanNEN less than 20 mm (rs = 0.472, 
95% CI from 0.121 to 0.718, p = 0.013) and greater than 20 mm (rs = 0.430, 95% 
CI from 0.124 to 0.661, p = 0.030).  
 With the endoscopic approach, the agreement was good (n = 54, rs = 0.610, 
95% CI from 0.409 to 0.755, p < 0.001). However, with the percutaneous approach, 
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the agreement was negative but not statistically significant (n = 9, rs = -0.253, 95% 
CI from -0.785 to 0.494, p = 0.511).  
Concordance rates for Ki-67 
 The mean index values of cKi-67 and hKi-67 were 4.35 ± 9.5% and 5.26 ± 
12% respectively (p = 0.334). The average ΔKi-67 was -0.7 ± 7.5%.  
 Spearman's rho was good for the overall population (rs = 0.615, 95% CI 
from 0.434 to 0.749, p < 0.001). When analyzing tumors less and greater than 20 
mm, the agreement was very good and moderate respectively (rs = 0.862, 95% CI 
from 0.7180 to 0.9359, p < 0.001; rs = 0.596, 95% CI from 0.329 to 0.775, p = 
0.0002). 
 Using the endoscopic approach, the agreement was moderate (n = 54, rs = 
0.558, 95% CI from 0.342 to 0.718, p < 0.001) while the percutaneous one was 
negative but not statistically significant (n = 9, rs = -0.217, 95% CI from -0.770 to 
0.552, p=0.534). 
 The Bland-Altman plot (Figure 1) shows an agreement between cKi-67 and 
hKi-67 assessment, as 95% of the data points lie within ± 1.96 SD of the limits of 
agreement26. Due to the skewness of the data (Figure 1A), we removed two outliers 
from the analysis and the limits of agreement reduced considerably (Figure 1B). 
Figure 1. Bland-Altman plot. A. Overall cohort. B. Subgroup analysis with 
exclusion of the outliers to correct the skewness of the data. 
A 
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Outliers of ΔKi-67 
 Twenty-six (39.4%) outliers were identified. The majority of these cases 
were found using eUS (n = 18, 69.2%) and the remaining using pUS (n = 8, 30.8%). 
In the univariate analysis, the pUS approach was more frequently associated with 
outliers than the eUS one (87.5% vs. 31.6%, p = 0.004). The mean diameter of the 
outliers was 36.4 ± 30.2 mm, while the consistent cases were 23.5 ± 12.2 mm in 
diameter (p = 0.001). The other variables considered (sex, age [≤ / > 50 years], 
symptoms [yes/no], tumor dimensions [≤ / > 20 mm], tumor site [head, neck, tail]) 
were not statistically significant. 
Discussion 
 Owing to the development of cross-sectional imaging and endoscopic 
examination, PanNENs have been increasingly detected and diagnosed over the 
past few decades27. An ensuing issue is whether all of these lesions need to be 
treated aggressively with surgery or whether they can be managed with 
surveillance. Currently, this choice is decided based on several features, including 
the tumor’s dimensions, site, metabolic activity, presumed biological behavior, and 
the patient’s wishes and comorbidities. The biological behavior is assessed using 
the Ki-67 index value and grading determined by FNA. In particular, in the era of 
 13 
personalized medicine, the assessment of grading accuracy is important to inform 
tailored treatment strategies (e.g. resection vs. surveillance or non-surgical 
treatments; standard vs. parenchyma-sparing resection). However, the literature 
contains heterogeneous reports of the concordance rate for PanNEN grading, 
ranging from 69% to 90% 28. In this study, we investigated whether cKi-67 and cG 
accurately represents hKi-67 and hG to establish the diagnostic concordance rates 
of FNA. 
 We found a very good diagnostic rate of 84% with all diagnoses being 
confirmed by final histology. These numbers are in line with previous findings17, 29-
31 and they highlight the reliability of the FNA-based diagnosis of PanNENs, apart 
from the cases with complex histology (mixed forms). 
 In regards to the grading concordance, we found an acceptable overall rate 
of 72.1%, which is a bit lower than previous reports28, 32-34. This rate was higher for 
G2 tumors (> 80%) and lower for G3 (33.3%). The overall agreement was moderate 
and we did not find any difference using the dimensional cut-off of 20 mm. Of note, 
11 of 47 (23.4%) cG1 PanNENs were found to actually be hG2 and 2 of 13 (15.3%) 
cG2 were actually hG1. Two FNA-determined G3 PanNENs were revealed to 
actually be G1 upon histological analysis and these were all biopsied 
percutaneously. They were performed at the beginning of our policy to biopsy 
PanNENs during the therapeutic work-up and at that time the eUS was not 
available. For G3 tumors, we might speculate that the ROSE was not informative 
and that additional immunocytochemical evaluation would have been helpful for 
these complex cases. However, it is likely that the heterogeneous architecture of a 
G3 tumor itself acted as a confounding factor. The agreement between the grading 
was good for eUS and negative for pUS, though this was not statistically significant. 
We hypothesize that this negative agreement from pUS is an “artifact” as the tumors 
biopsied using pUS were bigger and histologically complex and the patients were 
well-selected. Nevertheless, the small number of pUS-FNA cases mitigates our 
considerations. Taken together, the overall agreement between cG and hG was 
moderate and under-grading (n = 11) was more frequent than over-grading (n = 4). 
These findings have to somehow be considered at the time of therapeutic decision 
in order to select the optimal treatment course.  
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 In terms of concordance between Ki-67 index values, we discovered a small 
underestimation of cKi-67 compared to hKi-67 (mean difference of -0.7%). The 
overall correlation was good and very good (rs = 0.862) for tumors smaller than 20 
mm. This has already been described by other authors who found a negative 
correlation between the concordance rate for Ki-67 and the tumor dimensions, 
where the bigger the tumor, the higher the cellular heterogeneity, and the higher the 
risk of misestimation13, 32, 35.  
 From the analysis of the outliers of ΔKi-67 (n = 26, 39.3%), we found that 
pUS was significantly more associated with this result than eUS. These outlier cases 
were stastistically significant bigger tumors with, presumably, higher tissue 
heterogeneity. 
 Multiple lessons can be gleaned from the results of the present investigation, 
which represents the biggest cohort study published to date comparing the cytology 
and histology-based determinations of PanNENs. First, FNA is an effective 
diagnostic tool when facing a suspected PanNEN. It enables a high rate of 
diagnosis, excellent diagnostic concordance, and negligible to no side effects. 
Second, the grading assessment was satisfactory as it was accurate in about 75% of 
cases; however, under-grading is possible and must be considered. This finding 
might affect the therapeutic approach in peculiar cases where the optimal 
therapeutic approach is not clear. For example, small PanNENs with a doubtful 
metabolic activity (e.g. Ki-67 3-4%) and unclear lymphadenopathies may be 
classified as G1 with FNA and later be revealed as G2 at final histology and, thus, 
may benefit from surgery; or G2 tumors with potential vascular involvement may 
benefit from non-surgical oncological treatment as these are “true” G2 tumors at 
histology). Third, we found a very high agreement for Ki-67 index values when 
considering tumors less than 20 mm. This finding might help the therapeutic 
management of this sub-cohort of PanNENs where the therapy might be 
controversial (surgery vs. follow-up). Fourth, bigger PanNENs are more prone to 
misdiagnosis and have the highest levels of ΔKi-67. Fifth, in our institution, eUS-
FNA, even without a ROSE, reaches higher levels of concordance than pUS-FNA; 
therefore, this approach is preferable for ensuring an accurate diagnosis. 
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 This study also has some limitations that must be considered as well. We 
did not perform a survival analysis comparing the data from FNA and histology 
because we believed it was beyond the scope of this study. The pathologists were 
not blinded and the same pathologists might have performed both the cytology and 
histology for a single case. The choice to subject the patients to eUS or pUS was at 
the specialist’s discretion and this might have generated a selection bias. Moreover, 
ROSE was not available for eUS as it was at pUS and this might confound the 
comparison of the two techniques. Not all PanNENs who underwent surgery 
underwent FNA and this choice was at the surgeon’s discretion, which might have 
generated a selection bias. Finally, a review of the discordant and non-diagnostic 
cases that could’ve identified possible influencing factors was not performed. 
 In conclusion, in cases of suspected PanNEN, FNA is a reliable tool for 
assessing the tumor’s nature, especially using eUS. Preoperative cytological 
approaches may under-grade compared to the postoperative histology analyses. 
Nevertheless, we recommend this preoperative procedure for reaching a diagnosis 
in unclear cases, especially for small tumors, in order to classify subtypes, tailor 
treatments, and improve patient outcome. 
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